Last updated: October 21, 2026
Chlorpromazine hydrochloride is a mature, low-cost generic medicine with no meaningful remaining brand exclusivity in the United States. Its commercial trajectory is defined by declining use in routine psychosis treatment, persistent demand for low-cost injectable and oral formulations, fragmented generic supply, and limited manufacturer-specific financial disclosure. The product has little patent-driven value but can retain strategic importance where hospitals require inexpensive antipsychotic injections or clinicians use it for refractory hiccups, severe nausea, or legacy psychiatric indications.
What is the current market position of chlorpromazine hydrochloride?
Chlorpromazine hydrochloride is a first-generation phenothiazine antipsychotic marketed primarily as a generic. The original branded product, Thorazine, was introduced in the United States in the 1950s. Current supply is distributed through generic manufacturers and contract pharmaceutical suppliers rather than a dominant branded company.
| Market attribute |
Current position |
| Active ingredient |
Chlorpromazine hydrochloride |
| Drug class |
First-generation phenothiazine antipsychotic |
| Main dosage forms |
Tablets, oral concentrate, and injectable solution |
| U.S. regulatory status |
Approved prescription drug; predominantly generic |
| Original brand |
Thorazine |
| Current patent protection |
No material U.S. exclusivity expected |
| Biosimilar exposure |
None; chlorpromazine is a small-molecule drug |
| Commercial model |
Low-price, multi-source generic |
| Primary buyers |
Retail pharmacies, hospitals, government purchasers, wholesalers |
| Key commercial risk |
Supplier concentration and injectable availability |
| Main competitive pressure |
Atypical antipsychotics and other antiemetic or psychiatric therapies |
The product remains clinically relevant but is no longer a growth pharmaceutical. Its use is concentrated in specific patient populations and institutional settings. The FDA-approved labeling includes schizophrenia and other psychotic disorders, manic states, severe behavioral problems, nausea and vomiting, intractable hiccups, and selected perioperative or obstetric uses, depending on dosage form and label version (DailyMed, n.d.-a; DailyMed, n.d.-b).
How large is the chlorpromazine hydrochloride market?
A reliable current global market size is not publicly disclosed. Chlorpromazine hydrochloride is sold by multiple generic companies, and suppliers generally do not report product-level revenue in annual filings. Commercial estimates that aggregate all chlorpromazine products often combine different dosage forms, countries, channels, and manufacturers, limiting their usefulness for investment analysis.
The U.S. market is best understood as a small mature generic segment rather than a high-growth therapeutic market. Revenue is generated through unit volume and hospital procurement rather than premium pricing. Oral tablets and concentrates compete primarily on price and availability. Injectable chlorpromazine can command a higher price per unit than tablets, but total volume is smaller and manufacturing, quality, and inventory requirements are more demanding.
What drives demand?
Demand is supported by several factors:
- Continued use in schizophrenia and severe behavioral disorders when clinicians retain a first-generation antipsychotic strategy.
- Low acquisition cost compared with newer branded or long-acting antipsychotic products.
- Availability of injectable treatment for patients who cannot take oral medication.
- Use in less common indications such as persistent hiccups and severe nausea.
- Institutional formularies that maintain older medicines for therapeutic breadth.
Demand is constrained by:
- Lower use of first-generation antipsychotics in routine outpatient care.
- Greater prescribing of atypical antipsychotics such as risperidone, olanzapine, quetiapine, aripiprazole, and lurasidone.
- Adverse-effect concerns, including extrapyramidal symptoms, tardive dyskinesia, sedation, orthostatic hypotension, anticholinergic effects, and QT-related cardiac risk.
- Clinician preference for products with more favorable tolerability or dosing profiles.
- Generic substitution and price competition.
What is the financial trajectory for chlorpromazine hydrochloride?
The financial trajectory is structurally flat to declining in value, with periodic increases caused by shortages, supplier exits, or channel disruptions rather than by durable volume growth.
Historical trajectory
Chlorpromazine became a major early antipsychotic after its U.S. introduction in 1954. Its commercial value declined after patent protection ended and after newer antipsychotic therapies entered the market. The product subsequently transitioned from a branded innovation to a mature generic medicine.
The financial phases are:
| Period |
Commercial profile |
| 1950s to 1960s |
Branded innovation with substantial psychiatric use |
| 1970s onward |
Loss of exclusivity and generic competition |
| 1990s to 2000s |
Declining relative position as atypical antipsychotics expanded |
| 2010s |
Mature generic product with low pricing and fragmented supply |
| 2020s |
Stable niche demand, limited pricing power, and supply-chain sensitivity |
No current manufacturer appears to disclose a standalone chlorpromazine hydrochloride revenue stream. Product-level sales are generally immaterial relative to the consolidated revenue of major generic companies. Financial analysis therefore depends on prescription volume, dosage-form mix, supplier count, acquisition cost, and shortage conditions rather than reported company revenue.
What affects profitability?
Profitability differs sharply by dosage form. Tablets are relatively easy to manufacture and face substantial price pressure. Oral concentrates have more specialized packaging and distribution requirements. Injectable products require sterile manufacturing and quality controls, which can reduce the number of qualified suppliers and create higher operational risk.
The strongest commercial economics are likely to occur during temporary supply disruptions, but those conditions are unstable. A manufacturer that maintains reliable injectable capacity can gain hospital contracts or wholesaler share without owning patent rights. The principal barrier is execution, not intellectual property.
What patents protect chlorpromazine hydrochloride?
No material active U.S. patent estate is expected to protect the chlorpromazine hydrochloride molecule or its conventional dosage forms.
The original product was developed and commercialized decades before the current generic market. Any foundational compound or early product patents would have expired long ago. Current FDA generic listings do not create new patent exclusivity. The Orange Book identifies patent and exclusivity information for approved products where applicable, but mature chlorpromazine hydrochloride products are not generally protected by active patents that could block ordinary generic entry (U.S. Food and Drug Administration [FDA], n.d.-a).
| IP category |
Current commercial significance |
| Original compound patent |
Expired |
| Original branded formulation rights |
Expired or commercially obsolete |
| Active ingredient patent |
No material current protection |
| Tablet formulation patent |
No expected blocking estate |
| Injectable formulation patent |
No expected blocking estate |
| Method-of-use patent |
No material broad blocking protection expected |
| Manufacturing know-how |
Potentially relevant, but not publicly quantifiable |
| Regulatory exclusivity |
None expected for mature generic products |
Patent risk may still arise from a specific manufacturer’s process, packaging, or specialized formulation, but such rights would not normally prevent competitors from marketing conventional chlorpromazine hydrochloride products.
When did chlorpromazine hydrochloride lose exclusivity?
Chlorpromazine hydrochloride lost practical brand exclusivity decades ago. The exact historical patent sequence depends on the jurisdiction, dosage form, and product claim. For current U.S. commercial purposes, the relevant conclusion is that generic competition is fully established and no remaining exclusivity period controls market entry.
Is chlorpromazine hydrochloride listed in the Orange Book?
FDA-approved chlorpromazine hydrochloride products and related reference products may appear in FDA approval databases and the Orange Book under specific dosage forms and application histories. Orange Book status must be assessed by product, strength, dosage form, and application number rather than by active ingredient alone (FDA, n.d.-a).
The commercial significance is limited because:
- Generic approval pathways are already established.
- No current market exclusivity is expected to block additional abbreviated new drug applications.
- Any listed patents would need to be evaluated against the specific reference product and dosage form.
- A generic applicant could face regulatory requirements even where patent barriers are absent.
Are there Paragraph IV challenges involving chlorpromazine hydrochloride?
Paragraph IV litigation is not a central current market issue for conventional chlorpromazine hydrochloride. Paragraph IV certifications are most commercially important when an applicant seeks approval before the expiration of an Orange Book-listed patent. Because chlorpromazine hydrochloride is a long-established generic medicine with no apparent blocking patent estate, new Paragraph IV activity is unlikely to materially affect the market.
A company could still submit an ANDA with a Paragraph IV certification if it encountered a listed patent associated with a specific reference product. That event would require review of the relevant FDA listing and court docket. It would not change the broader conclusion that the active ingredient is open to generic competition.
What formulations are protected or commercially differentiated?
Conventional tablets, oral concentrates, and injections have little apparent patent differentiation. Commercial differentiation instead comes from manufacturing reliability, package configuration, channel access, and regulatory compliance.
Oral tablets
Tablets are the most commoditized form. Buyers typically focus on price, supplier reliability, bottle sizes, and wholesaler availability. A manufacturer with multiple approved strengths can improve formulary coverage, but the product remains vulnerable to substitution.
Oral concentrate
The concentrate may have greater operational complexity because of dosing accuracy, packaging, labeling, and storage requirements. These factors can reduce the number of practical suppliers even when legal barriers are absent.
Injectable solution
The injectable product has the strongest potential supply-side differentiation. Sterile manufacturing, inspection readiness, batch-release controls, and hospital procurement requirements create higher entry costs. Those costs are manufacturing barriers rather than patent barriers.
What FDA regulatory status applies to chlorpromazine hydrochloride?
Chlorpromazine hydrochloride is an FDA-approved prescription medicine sold through both reference-product and abbreviated generic pathways, depending on the specific product. FDA approval does not guarantee continuous commercial availability. Products can be approved but inactive, discontinued, or unavailable from a particular supplier.
The most important regulatory variables are:
- Whether the product has an active FDA application.
- Whether the manufacturer is currently producing the dosage form.
- Whether the product is listed as available or in shortage.
- Whether the supplier has recent manufacturing or quality actions.
- Whether a hospital buyer requires a particular dosage form or package configuration.
FDA’s Drugs@FDA database and Orange Book should be reviewed at the product level because application status can differ among tablets, concentrates, and injections (FDA, n.d.-a; FDA, n.d.-b).
What generic entry risks exist?
Generic entry risk is high because the active ingredient is old, the clinical profile is established, and patent barriers are minimal. The market can support several suppliers, but actual competition may be narrower for injectable and specialized products.
| Risk category |
Assessment |
| Patent blocking risk |
Low |
| Regulatory approval risk |
Moderate, depending on dosage form |
| Formulation development risk |
Low for conventional tablets; higher for sterile injection |
| Price erosion risk |
High |
| Supply disruption risk |
Moderate to high |
| Substitution risk from newer therapies |
High |
| Hospital contracting risk |
Moderate |
| Biosimilar risk |
Not applicable |
A new oral-tablet entrant would face substantial price competition and limited differentiation. An injectable entrant could have a stronger commercial rationale if it demonstrates reliable supply, competitive pricing, and hospital distribution.
Which companies compete in chlorpromazine hydrochloride?
The competitive field consists of generic pharmaceutical manufacturers, specialty suppliers, and distributors. Supplier participation may vary by dosage form and market. Major generic companies have historically marketed chlorpromazine or related phenothiazine products, but current active commercialization must be verified against FDA listings and supplier catalogs.
The relevant competitive categories are:
- Large generic manufacturers with broad psychiatric portfolios.
- Specialty manufacturers focused on hospital injectables.
- Contract manufacturers supplying distributors.
- Wholesalers and repackagers.
- Regional suppliers serving government and institutional contracts.
Company-level revenue attribution is difficult because chlorpromazine is usually bundled within broader generic portfolios. Public filings generally do not identify sales, gross margin, or market share for the molecule separately.
How does chlorpromazine compare with newer antipsychotics?
Chlorpromazine has a cost advantage but a weaker tolerability and convenience profile.
| Attribute |
Chlorpromazine hydrochloride |
Atypical antipsychotics |
| Patent status |
Mature generic |
Mix of generic and branded products |
| Acquisition cost |
Low |
Ranges from low generic cost to high branded cost |
| Extrapyramidal risk |
Clinically important |
Varies by product |
| Sedation and hypotension |
Common concerns |
Varies by product |
| Long-acting options |
Limited relevance |
Available for several agents |
| Outpatient prescribing momentum |
Limited |
Stronger for many newer agents |
| Hospital niche use |
Persistent |
Broad |
| Pricing power |
Minimal |
Higher for differentiated or branded products |
Chlorpromazine remains useful where clinicians value low cost, established experience, or a specific indication. It is less competitive where reduced sedation, lower movement-disorder risk, metabolic considerations, or long-acting administration are priorities.
What licensing deals and settlement agreements affect the market?
No major current licensing deal or patent settlement is known to define the commercial market for conventional chlorpromazine hydrochloride. The drug’s economic model is based on generic supply rather than proprietary licensing.
Any transaction involving chlorpromazine would more likely concern:
- A portfolio acquisition.
- A contract manufacturing arrangement.
- A hospital-supply agreement.
- A product transfer between generic companies.
- A regional distribution contract.
These arrangements may affect availability but are unlikely to create durable market exclusivity.
What is the geographic coverage of chlorpromazine hydrochloride?
Chlorpromazine is marketed internationally, but availability and dosage forms differ by country. The United States has a mature generic market. European and other markets may use different brand names, regulatory classifications, package sizes, or national reimbursement rules.
Geographic commercial performance depends on:
- National essential-medicine policies.
- Hospital procurement systems.
- Local generic pricing rules.
- Availability of injectable manufacturing.
- Psychiatric treatment guidelines.
- Registration status for specific dosage forms.
Global revenue estimates should not be treated as directly comparable because some markets report public procurement prices while others rely on private pharmacy channels.
Key Takeaways
- Chlorpromazine hydrochloride is a mature, low-price generic with no meaningful current U.S. patent exclusivity.
- Its financial trajectory is flat to declining, with temporary revenue or price increases driven by shortages rather than therapeutic growth.
- Tablets face severe generic price competition.
- Injectable products have greater commercial value because sterile manufacturing and hospital supply requirements limit practical competition.
- Newer atypical antipsychotics have reduced chlorpromazine’s routine prescribing share.
- Biosimilar risk is irrelevant because chlorpromazine is a small-molecule drug.
- Paragraph IV litigation, licensing deals, and settlement agreements are not major current market drivers.
- Product-level revenue and market-share data are generally unavailable from public company filings.
- The strongest commercial opportunity is reliable supply of hospital-relevant dosage forms, not patent protection.
FAQs
Is chlorpromazine hydrochloride still commercially available?
Yes. Availability depends on dosage form, strength, manufacturer, and distribution channel. A product may remain FDA-approved while being unavailable from a specific supplier.
Is Thorazine still sold in the United States?
Thorazine is the historical brand associated with chlorpromazine. Current U.S. supply is primarily generic, and brand availability may differ from the availability of generic chlorpromazine hydrochloride.
Does chlorpromazine hydrochloride have orphan-drug exclusivity?
No current orphan-drug exclusivity is expected to control the conventional U.S. chlorpromazine market.
Can a new company profitably launch chlorpromazine injection?
Potentially, but the opportunity depends on sterile manufacturing capacity, hospital contracts, regulatory compliance, and reliable supply. Patent ownership is unlikely to be the principal barrier.
What is the investment outlook for chlorpromazine hydrochloride?
The product has limited standalone growth potential. Investment value is more likely to come from portfolio scale, manufacturing efficiency, shortage-driven supply opportunities, or hospital-channel access than from pricing power or intellectual property.
References
DailyMed. (n.d.-a). Chlorpromazine hydrochloride tablet, film coated: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
DailyMed. (n.d.-b). Chlorpromazine hydrochloride injection: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
